Omnicell, Inc. (NASDAQ:OMCL) Receives Average Rating of “Hold” from Analysts

Omnicell, Inc. (NASDAQ:OMCL) has been given a consensus recommendation of “Hold” by the six ratings firms that are covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $52.00.

A number of research firms have weighed in on OMCL. Benchmark reaffirmed a “buy” rating and set a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. Wells Fargo & Company raised their target price on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research note on Monday, October 14th. Bank of America reissued a “neutral” rating and set a $57.00 price objective (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Barclays boosted their target price on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Finally, StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th.

Omnicell Stock Performance

Shares of OMCL opened at $44.32 on Friday. The stock has a fifty day moving average of $46.05 and a two-hundred day moving average of $40.35. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $55.74. The company has a market capitalization of $2.05 billion, a PE ratio of -113.64, a price-to-earnings-growth ratio of 34.96 and a beta of 0.77.

Insider Activity

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the transaction, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.64% of the stock is owned by insiders.

Hedge Funds Weigh In On Omnicell

A number of hedge funds have recently modified their holdings of the stock. Franklin Resources Inc. raised its position in Omnicell by 49.9% during the third quarter. Franklin Resources Inc. now owns 30,807 shares of the company’s stock valued at $1,316,000 after buying an additional 10,260 shares during the period. Geode Capital Management LLC raised its position in shares of Omnicell by 0.3% in the third quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock valued at $48,176,000 after purchasing an additional 2,877 shares during the period. Pier Capital LLC acquired a new position in shares of Omnicell during the 3rd quarter worth about $5,859,000. SageView Advisory Group LLC acquired a new stake in shares of Omnicell in the third quarter worth $480,000. Finally, ArrowMark Colorado Holdings LLC lifted its stake in shares of Omnicell by 27.1% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company’s stock valued at $49,742,000 after buying an additional 243,353 shares during the period. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.